ReviewThe AAPS journal2017
Nanomaterial Drug Products: Manufacturing and Analytical Perspectives.
Review in The AAPS journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Current state of nanomedicine drug products: An industry perspective.Journal of pharmaceutical sciences · 2024Article
- Single Particle Chemical Characterisation of Nanoformulations for Cargo Delivery.The AAPS journal · 2023Review
- Nanoparticle surface coatings produce distinct antibacterial effects that are consistent across diverse bacterial species.Frontiers in toxicology · 2023Article
- Identification of Molecular Fragments in Equilibrium with Polysiloxane Ultrasmall Nanoparticles.Nanomaterials (Basel, Switzerland) · 2022Article
- Recent Advances in Nano-Formulations for Skin Wound Repair Applications.Drug design, development and therapy · 2022Review
- Hazard Assessment of Polymeric Nanobiomaterials for Drug Delivery: What Can We Learn From Literature So Far.Frontiers in bioengineering and biotechnology · 2019Review
- Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.Nanomedicine (London, England) · 2019Review
- Synthesis and characterization of nanometer-sized liposomes for encapsulation and microRNA transfer to breast cancer cells.International journal of nanomedicine · 2019Article
- Cytotoxicological pathways induced after nanoparticle exposure: studies of oxidative stress at the 'nano-bio' interface.Toxicology research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing use of nanotechnology, including nanoparticles, in the preparation of drug products requires both manufacturing and analytical considerations in order to establish the quality metrics suitable for performance and risk assessment. A range of different nanoparticle systems exists including (but not limited to) nano-drugs, nano-additives, and nano-carriers. These systems generally require more complex production and characterization strategies than conventional pharmaceutical dosage forms. The advantage of using nanoparticle systems in pharmaceutical science is that the effective and desired function of the material can be designed through modern manufacturing processes. This paper offers a systematic nomenclature which allows for greater understanding of the drug product under evaluation based on available data from other nanoparticle reports. Analytical considerations of nano-drugs, nano-additives, and nano-carriers and the way in which they are measured are directly connected to quality control. Ultimately, the objective is to consider the entire nano-drug, nano-additive, and nano-carrier product life cycle with respect to its manufacture, use, and eventual fate. The tools and approaches to address the needs of these products exist; it should be the task of the pharmaceutical scientists and those in related disciplines to increase their understanding of nanomedicine and its novel products.
Indexed as
Identifiers
27822601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.